Recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
To evaluate the potential usefulness of 18F-AIPF-1026 positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-A-related disease patients.
ClinicalTrials.gov IDNCT07685860
PhaseNot Applicable
Enrollment200
SponsorTianjin Medical University
Age18 Years and older
SexALL
Conditions studied
Depression, Anxiety, Heart Injuries
About this study
To evaluate the potential usefulness of 18F-AIPF-1026 positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-A-related disease patients.
Interventions
- Diagnostic Test: Diagnostic Test: 18F-AIPFA-1026 — Each subject receive a single intravenous injection of 18F-AIPF-1026, and undergo PET/ CT or MRI imaging within the specificed time.
Primary outcomes
- Standardized uptake value (SUV) (30 days)
Eligibility information
Inclusion Criteria:
\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated depression (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled MAO-A PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Study locations
- The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230000 China
- The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000 China
- Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality 300052 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.